Low-Carbohydrate and Low-Fat Diet with Metabolic-Dysfunction-Associated Fatty Liver Disease.
low-carbohydrate diet
low-fat diet
metabolic-dysfunction-associated fatty liver disease
quality of macronutrients
severe fibrosis
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
13 Nov 2023
13 Nov 2023
Historique:
received:
13
10
2023
revised:
08
11
2023
accepted:
11
11
2023
medline:
27
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
This observational cross-sectional study was designed to explore the effects of a low-carbohydrate diet (LCD) and a low-fat diet (LFD) on metabolic-dysfunction-associated fatty liver disease (MAFLD). This study involved 3961 adults. The associations between LCD/LFD scores and MAFLD were evaluated utilizing a multivariable logistic regression model. Additionally, a leave-one-out model was applied to assess the effect of isocaloric substitution of specific macronutrients. Participants within the highest tertile of healthy LCD scores (0.63; 95% confidence interval [CI], 0.45-0.89) or with a healthy LFD score (0.64; 95%CI, 0.48-0.86) faced a lower MAFLD risk. Furthermore, compared with tertile 1, individuals with unhealthy LFD scores in terile 2 or tertile 3 had 49% (95%CI, 1.17-1.90) and 77% (95%CI, 1.19-2.63) higher risk levels for MAFLD, respectively. Healthy LCD and healthy LFD are protective against MAFLD, while unhealthy LFD can increase the risk of MAFLD. Both the quantity and quality of macronutrients might have significant influences on MAFLD.
Sections du résumé
BACKGROUND
BACKGROUND
This observational cross-sectional study was designed to explore the effects of a low-carbohydrate diet (LCD) and a low-fat diet (LFD) on metabolic-dysfunction-associated fatty liver disease (MAFLD).
METHODS
METHODS
This study involved 3961 adults. The associations between LCD/LFD scores and MAFLD were evaluated utilizing a multivariable logistic regression model. Additionally, a leave-one-out model was applied to assess the effect of isocaloric substitution of specific macronutrients.
RESULTS
RESULTS
Participants within the highest tertile of healthy LCD scores (0.63; 95% confidence interval [CI], 0.45-0.89) or with a healthy LFD score (0.64; 95%CI, 0.48-0.86) faced a lower MAFLD risk. Furthermore, compared with tertile 1, individuals with unhealthy LFD scores in terile 2 or tertile 3 had 49% (95%CI, 1.17-1.90) and 77% (95%CI, 1.19-2.63) higher risk levels for MAFLD, respectively.
CONCLUSIONS
CONCLUSIONS
Healthy LCD and healthy LFD are protective against MAFLD, while unhealthy LFD can increase the risk of MAFLD. Both the quantity and quality of macronutrients might have significant influences on MAFLD.
Identifiants
pubmed: 38004162
pii: nu15224763
doi: 10.3390/nu15224763
pmc: PMC10674227
pii:
doi:
Substances chimiques
Carbohydrates
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Department of Education of Jilin Province
ID : JJKH20231145KJ
Références
Clin Nutr. 2019 Apr;38(2):682-688
pubmed: 29705061
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
Liver Int. 2022 Jan;42(1):69-79
pubmed: 34521152
Cell Metab. 2018 Mar 6;27(3):559-571.e5
pubmed: 29456073
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
Diabetologia. 2022 Mar;65(3):506-517
pubmed: 34993571
Gut. 2019 Jan;68(1):83-93
pubmed: 29097438
Hepatology. 2023 Mar 1;77(3):942-948
pubmed: 35776631
Biomed Pharmacother. 2017 Dec;96:798-811
pubmed: 29078257
Nat Sci Sleep. 2021 Jan 29;13:103-111
pubmed: 33542668
Metabolism. 2021 Nov;124:154873
pubmed: 34478753
Int J Mol Sci. 2021 Mar 13;22(6):
pubmed: 33805788
BMJ. 2020 Mar 5;368:m511
pubmed: 32139373
Clin Nutr. 2019 Dec;38(6):2504-2520
pubmed: 30655101
Cancers (Basel). 2021 Dec 31;14(1):
pubmed: 35008356
J Clin Transl Hepatol. 2022 Apr 28;10(2):329-338
pubmed: 35528971
Liver Int. 2020 Jun;40(6):1254-1261
pubmed: 32301554
Vital Health Stat 2. 2018 Feb;(178):1-63
pubmed: 29775432
Am J Clin Nutr. 2015 Sep;102(3):556-72
pubmed: 26269373
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
J Nutr. 2006 Oct;136(10):2594-9
pubmed: 16988132
N Engl J Med. 2013 Nov 21;369(21):2001-11
pubmed: 24256379
Aliment Pharmacol Ther. 2013 Jan;37(1):3-17
pubmed: 23121117
Nutrients. 2022 Oct 26;14(21):
pubmed: 36364767
JAMA Intern Med. 2016 Oct 01;176(10):1453-1463
pubmed: 27479196
Ann Intern Med. 2023 Jan;176(1):10-21
pubmed: 36508737
Am J Clin Nutr. 2008 Aug;88(2):324-32
pubmed: 18689367
Metabolism. 2021 Feb;115:154433
pubmed: 33212070
JAMA Intern Med. 2020 Apr 1;180(4):513-523
pubmed: 31961383
J Hepatol. 2017 May;66(5):1022-1030
pubmed: 28039099
BMJ. 2018 Jun 13;361:k2340
pubmed: 29898880
Hepatology. 2021 Jan;73(1):175-185
pubmed: 32222996
Arch Intern Med. 2006 Feb 13;166(3):285-93
pubmed: 16476868
Obesity (Silver Spring). 2022 Nov;30(11):2317-2328
pubmed: 36058841
Nutrients. 2020 Oct 28;12(11):
pubmed: 33126575
Prog Lipid Res. 2013 Jan;52(1):165-74
pubmed: 23178552
Food Res Int. 2018 Jan;103:84-102
pubmed: 29389647
Clin Gastroenterol Hepatol. 2021 Oct;19(10):2138-2147.e10
pubmed: 33348045
Nutrients. 2015 Aug 21;7(8):7058-69
pubmed: 26308049
Circulation. 2017 Jul 18;136(3):e1-e23
pubmed: 28620111
Sci Data. 2016 Oct 25;3:160096
pubmed: 27779619
Diabetes Care. 2023 Apr 1;46(4):874-884
pubmed: 36787923
Front Nutr. 2022 May 02;9:867378
pubmed: 35586739
Age Ageing. 2022 Oct 6;51(10):
pubmed: 36315430
Nature. 2013 Aug 29;500(7464):541-6
pubmed: 23985870
Gastroenterology. 2019 May;156(6):1717-1730
pubmed: 30689971
Front Med. 2021 Jun;15(3):460-471
pubmed: 34185279
Diabetes. 2014 Jul;63(7):2356-68
pubmed: 24550191
J Hepatol. 2010 Aug;53(2):326-34
pubmed: 20462650
Ann Intern Med. 2014 Sep 2;161(5):309-18
pubmed: 25178568